ConductScience.org, home
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
API referenceFor AI assistants

Trial · NCT04182204

Results by group210

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 210

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Stage 1: Number of Participants With Adverse Events (AEs)Stage 1: Pola-R-GemOx14Participants
Stage 1: Number of Participants With Peripheral Neuropathy (PN)Stage 1: Pola-R-GemOx8Participants
Stage 2: Overall Survival (OS)Stage 2: R-GemOx12.595% Confidence Interval 8.9 to 15.8months
Stage 2: Overall Survival (OS)Stage 2: Pola-R-GemOx19.595% Confidence Interval 13.3 to NAmonths
Stage 1 and Stage 2: Progression-free Survival (PFS)Stage 1: Pola-R-GemOx3.995% Confidence Interval 3.0 to 6.3months
Stage 1 and Stage 2: Progression-free Survival (PFS)Stage 2: R-GemOx2.795% Confidence Interval 2.4 to 3.3months
Stage 1 and Stage 2: Progression-free Survival (PFS)Stage 2: Pola-R-GemOx7.495% Confidence Interval 6.2 to 11.7months
Stage 2: Complete Response Rate (CRR), as Determined by an Independent Review Committee (IRC) at the End of TreatmentStage 2: R-GemOx19.095% Confidence Interval 12.60 to 27.00percentage of participants
Stage 2: Complete Response Rate (CRR), as Determined by an Independent Review Committee (IRC) at the End of TreatmentStage 2: Pola-R-GemOx40.395% Confidence Interval 31.77 to 49.30percentage of participants
Stage 2: Objective Response Rate (ORR) as Determined by an IRC at End of TreatmentStage 2: R-GemOx24.695% Confidence Interval 17.37 to 33.07percentage of participants
Stage 2: Objective Response Rate (ORR) as Determined by an IRC at End of TreatmentStage 2: Pola-R-GemOx52.795% Confidence Interval 43.74 to 61.56percentage of participants
Stage 1 and Stage 2: Percentage of Participants With Best Overall Response (BOR) as Determined by the InvestigatorStage 1: Pola-R-GemOx46.795% Confidence Interval 21.27 to 73.41percentage of participants
Stage 1 and Stage 2: Percentage of Participants With Best Overall Response (BOR) as Determined by the InvestigatorStage 2: R-GemOx34.995% Confidence Interval 26.65 to 43.92percentage of participants
Stage 1 and Stage 2: Percentage of Participants With Best Overall Response (BOR) as Determined by the InvestigatorStage 2: Pola-R-GemOx65.195% Confidence Interval 56.23 to 73.29percentage of participants
Stage 1 and Stage 2: CRR as Determined by the Investigator at End of TreatmentStage 1: Pola-R-GemOx20.095% Confidence Interval 4.33 to 48.09percentage of participants
Stage 1 and Stage 2: CRR as Determined by the Investigator at End of TreatmentStage 2: R-GemOx18.395% Confidence Interval 11.94 to 26.12percentage of participants
Stage 1 and Stage 2: CRR as Determined by the Investigator at End of TreatmentStage 2: Pola-R-GemOx35.795% Confidence Interval 27.42 to 44.57percentage of participants
Stage 1 and Stage 2: ORR as Determined by the Investigator at End of TreatmentStage 1: Pola-R-GemOx26.795% Confidence Interval 7.79 to 55.10percentage of participants
Stage 1 and Stage 2: ORR as Determined by the Investigator at End of TreatmentStage 2: R-GemOx24.695% Confidence Interval 17.37 to 33.07percentage of participants
Stage 1 and Stage 2: ORR as Determined by the Investigator at End of TreatmentStage 2: Pola-R-GemOx45.095% Confidence Interval 36.20 to 53.96percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04182204/results

API referenceFor AI assistants